Antibiotic use and the risk of lung cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 6, 2008, Pages 1308-1315

  Zhang, Hui ^a   García Rodríguez, Luis A ^b   Hernández Díaz, Sonia ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b Spanish Center of Pharmacoepidemiologic Research ^*  (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEFALEXIN; CEPHALOSPORIN DERIVATIVE; COTRIMOXAZOLE; ERYTHROMYCIN; FLUCLOXACILLIN; MACROLIDE; OXYTETRACYCLINE; PENICILLIN DERIVATIVE; PENICILLIN V; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE DERIVATIVE; TRIMETHOPRIM;

ADULT; AGED; ARTICLE; BODY MASS; CANCER RISK; CARCINOGENICITY; CASE CONTROL STUDY; CHRONIC OBSTRUCTIVE LUNG DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG USE; FEMALE; HEALTH CARE UTILIZATION; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESPIRATORY TRACT INFECTION; RISK ASSESSMENT; RISK FACTOR; SMOKING;

AGED; ANTI-BACTERIAL AGENTS; BIAS (EPIDEMIOLOGY); CASE-CONTROL STUDIES; CAUSALITY; CONFIDENCE INTERVALS; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RISK ASSESSMENT; SPAIN;

EID: 53349119031     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-07-2817     Document Type: Article

References (44)

1. Kato I, Koenig KL, Baptiste MS. History of antibiotic use and risk of non-Hodgkin's lymphoma (NHL). Int J Cancer 2003;107:105.
2. Chang ET, Smedby KE, Hjalgrim H, et al. Medication use and risk of non-Hodgkin's lymphoma. Am J Epidemiol 2005;162:965-74.
3. Didham RC, Reith DM, McConnell DW, Harrison KS. Antibiotic exposure and breast cancer in New Zealand. Breast Cancer Res Treat 2005;92:163-7.
4. Knekt P, Adlercreutz H, Rissanen H, et al. Does antibiotic treatment for urinary tract infection contribute to the risk of breast cancer? Br J Cancer 2000;82:1107-10.
5. Velicer CM, Heckbert SR, Lampe JW, Potter JD, Robertson CA, Taplin SH. Antibiotic use in relation to the risk of breast cancer. JAMA 2004;291:827-35.
6. Garcia Rodriguez LA, Gonzalez-Perez A. Use of antibiotics and risk of breast cancer. Am J Epidemiol 2005;161:616-9.
7. Kaye JA, Jick H. Antibiotics and the risk of breast cancer. Epidemiol Sep 2005;16:688-90.
8. Sørensen HT, Skriver MV, Friis S, McLaughlin JK, Blot WJ, Baron JA. Use of antibiotics and risk of breast cancer: a population-based case-control study. Br J Cancer 2005;92:594-6.
9. Friedman GD, Oestreicher N, Chan J, Quesenberry CP, Jr., Udaltsova N, Habel LA. Antibiotics and risk of breast cancer: up to 9 years of follow-up of 2.1 million women. Cancer Epidemiol Biomarkers Prev 2006;15:2102-6.
10. Selby JV, Friedman GD, Fireman BH. Screening prescription drugs for possible carcinogenicity: eleven to fifteen years of follow-up. Cancer Res 1989;49:5736-47.
11. Bourke A, Dattani H, Robinson M. Feasibility study and methodology to create a quality-evaluated database of primary care data. Inform Prim Care 2004;12:171-7.
12. Hernandez-Diaz S, Garcia Rodriguez LA. Nonsteroidal anti-inflammatory drugs and risk of lung cancer. Int J Cancer 2007;120:1565-72.
13. Pearl J. Causal inference from indirect experiments. Artif Intell Med 1995;7:561-82.
14. Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiology 1999;10:37-48.
15. Ferlay J, Bray F, Pisani P, Parkin D. GLOBOCAN 2002: Cancer incidence, mortality and prevalence worldwide. IARC CancerBase no. 5, version 2.0. Lyon: IARC Press; 2004.
16. Snyder RD, Green JW. A review of the genotoxicity of marketed pharmaceuticals. Mutat Res 2001;488:151-69.
17. Robbana-Barnat S, Decloitre F, Frayssinet C, Seigneurin JM, Toucas L, Lafarge-Frayssinet C. Use of human lymphoblastoid cells to detect the toxic effect of chloramphenicol and metabolites possibly involved in aplastic anemia in man. Drug Chem Toxicol 1997;20:239-53.
18. Corbett GM, Perry DJ, Shaw TR. Penicillin-induced leukopenia. N Engl J Med 1982;307:1642-3.
19. Homayouni H, Gross PA, Setia U, et al. Leukopenia due to penicillin and cephalosporin homologues. Arch Int Med 1979:827-8.
20. Roe FJ. Toxicologic evaluation of metronidazole with particular reference to carcinogenic, mutagenic, and teratogenic potential. Surgery 1983;93:158-64.
21. Majima T, Mikasa K, Sakamoto M, et al. Administration of clarithromycin (CAM) to non-small cell lung cancer. Jpn J Antibiot 2000;53:52-5.
22. Sasaki M, Ito T, Fukui S, et al. Effect of 14-membered ring macrolides on heparanase mRNA expression in lung cancer cells. Jpn J Antibiot 2001;54:97-100.
23. Yatsunami J, Tsuruta N, Hara N, Hayashi S. Inhibition of tumor angiogenesis by roxithromycin, a 14-membered ring macrolide antibiotic. Cancer Lett 1998;131:137-43.
24. Oosterheert JJ, Bonten MJ, Hak E, Schneider MM, Hoepelman IM. How good is the evidence for the recommended empirical antimicrobial treatment of patients hospitalized because of community-acquired pneumonia? A systematic review. J Antimicrob Chemother 2003;52:555-63.
25. Kuyvenhoven M, Van Essen G, Schellevis F, Verheij T. Management of upper respiratory tract infections in Dutch general practice; antibiotic prescribing rates and incidences in 1987 and 2001. Fam Pract 2006;23:175-9.
26. O'Byrne KJ, Dalgleish AG. Infection and cancer. Lancet 2001;358:156.
27. Evans AS, Mueller NE. Viruses and cancer. Causal associations. Ann Epidemiol 1990;1:71-92.
28. Zheng W, Blot WJ, Liao ML, et al. Lung cancer and prior tuberculosis infection in Shanghai. Br J Cancer 1987;56:501-4.
29. Aoki K. Excess incidence of lung cancer among pulmonary tuberculosis patients. Jpn J Clin Oncol 1993;23:205-20.
30. Herrera LA, Benitez-Bribiesca L, Mohar A, Ostrosky-Wegman P. Role of infectious diseases in human carcinogenesis. Environ Mol Mutagen 2005;45:284-303.
31. Ardies CM. Inflammation as cause for scar cancers of the lung. Integr Cancer Ther 2003;2:238-46.
32. Littman AJ, Thornquist MD, White E, Jackson LA, Goodman GE, Vaughan TL. Prior lung disease and risk of lung cancer in a large prospective study. Cancer Causes Control 2004;15:819-27.
33. Wu AH, Fontham ET, Reynolds P, et al. Previous lung disease and risk of lung cancer among lifetime nonsmoking women in the United States. Am J Epidemiol 1995;141:1023-32.
34. Ramanakumar AV, Parent ME, Menzies D, Siemiatycki J. Risk of lung cancer following nonmalignant respiratory conditions: evidence from two case-control studies in Montreal, Canada. Lung Cancer 2006;53:5-12.
35. Brownson RC, Alavanja MC. Previous lung disease and lung cancer risk among women (United States). Cancer Causes Control 2000;11:853-8.
36. Kocazeybek B. Chronic Chlamydophila pneumoniae infection in lung cancer, a risk factor: a case-control study. J Med Microbiol 2003;52:721-6.
37. Littman AJ, Jackson LA, Vaughan TL. Chlamydia pneumoniae and lung cancer: epidemiologic evidence. Cancer Epidemiol Biomarkers Prev 2005;14:773-8.
38. Chen YC, Chen JH, Richard K, Chen PY, Christiani DC. Lung adenocarcinoma and human papillomavirus infection. Cancer 2004;101:1428-36.
39. Ohshima H, Bartsch H. Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutat Res 1994;305:253-64.
40. Shacter E, Weitzman SA. Chronic inflammation and cancer. Oncology Williston Park 2002;16:217-26, 229;discussion 230-2.
41. O'Byrne KJ, Dalgleish AG. Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer 2001;85:473-83.
42. Hernan MA, Hernandez-Diaz S, Robins JM. A structural approach to selection bias. Epidemiology 2004;15:615-25.
43. Robins JM, Greenland S. Identifiability and exchangeability for direct and indirect effects. Epidemiology 1992;3:143-55.
44. Cole SR, Hernan MA. Fallibility in estimating direct effects. Int J Epidemiol 2002;31:163-5.